New antiepileptic drugs in childhood

Panminerva Medica

Volumn 44, Issue 3, 2002, Pages 221-225

  Verrotti, A ^a   Trotta, D ^a   Morgese, G ^b   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Administration and dosage; Anticonvulsants; Child; Epilepsy, drug therapy

Indexed keywords

ANTICONVULSIVE AGENT;

CHILD; DOSE RESPONSE; EPILEPSY; HUMAN; REVIEW;

ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS;

EID: 0036716019     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention. Prevalence of self-reported epilepsy - United States, 1986-1990. MMWR Morb Mortal Wkly Rep 1994;43:810-25.
2. Sperling MR, Feldman H, Kinman J. Seizure control and mortality in epilepsy. Ann Neurol 1999;46:45-50.
3. Morton LD, Pellock JM. Diagnosis and treatment of epilepsy in children and adolescents. Drugs 1996;51:399-414.
4. Blum DE. New drugs for persons with epilepsy. Adv Neurol 1998;76:57-87.
5. Datta PK, Crawford PM. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 2000;9:51-7.
6. Wong IC, Lhatoo SD. Adverse reactions to new antiepileptic drugs. Drug Saf 2000;23:35-56.
7. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorder of motor function. Drugs 1991;43:889-926.
8. Mattson RH, Petroff O, Rothman D. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spetroscopy. Epilepsia 1994;35(Suppl 5):29-32.
9. Fois A, Buoni S, Di Bartolo RM, Di Marco V, Mostardini R. Vigabatrin treatment in children. Childs Nerv Syst 1994;10:244-8.
10. Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56:605-7.
11. Chadwick D, for the Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomesed double-blind study. Lancet 1999;354:13-9.
12. Kalviainen R, Aikia M, Saukkonen AM, Mervaala, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized controlled study. Arch Neurol 1995;52:989-96.
13. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs. A systematic review of their efficacy and tolerability. Br Med J 1996;313:1169-74.
14. Schmidt B, Wohlrab G, Boltshauser E. Vigabatrin in newly diagnosed infantile spasms. Neuropediatr 1994;25(1):54-7.
15. Vigevano F, Cilio MR, Faberi A. Vigabatrin versus ACTH in the treatment of infantile spasms. Epilepsia 1995;38:1270-4.
16. Riikonen RS. West syndrome. Steroids or vigabatrin in the treatment of infantile spasms? Pediatr Neurol 2000;23:403-8.
17. Arndt CF, Darambure P, Defoort-Dhellemmes S. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:1201-5.
18. Elke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:180-1.
19. Bourgeois BF. New antiepileptic drugs. Arch Neurol 1998;55:1181-3.
20. Schmidt D, Perucca E. La terapia farmacologica delle epilessie. Milano: Mediserve, 1997.
21. Perucca E. Recipes for clinical pratice. In: Trimble MR, editor. New anticonvulsants: advances in the treatment of epilepsy. Chichester: John Wiley & Sons, 1994:145-57.
22. Brodie MJ, Richens, Yuen WC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;354:476-9.
23. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44(Suppl 8):29-35.
24. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy. A double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
25. Collins TL, Petroff OA, Mattson RH. A comparison of four new antiepileptic medications. Seizure 2000;9:291-3.
26. Buoni S, Grosso S, Fois A. Lamotrigine treatment in childhood drug resistent epilesy. J Child Neurol 1998;13:163-7.
27. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997;12:29-37.
28. Verrotti A, Domizio S, Angelozzi B, Chiarelli F, Sabatino G. Lamotrigine-related rash. Int J Immunopathol Pharmacol 1997;10:159-62.
29. Iannetti P, Raucci U, Zuccaro P, Pacifici R. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998;39:502-7.
30. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;26:27-34.
31. Coffin V, Cohen-Williams M, Barnett A. Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur J Pharmacol 1994;256:R9-10.
32. Ticku MK, Kamatchi GL, Sofia RD. Effect of anticonvulsant felbamate on GABA receptor system. Epilepsia 1991;32:389-91.
33. Leppik IE, Dreifuss FE, Pledger GW. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41:1785-9.
34. Theodore WH, Raubertas RF, Porter RJ. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991;32:392-7.
35. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (LGS). N Engl J Med 1993;328:29-34.
36. Raucci U, Pelliccia A, Corcelli A, Borghese R, Colangelo C. La gestione delle epilessie resistenti: ruolo dei nuovi farmaci topiramato e felbamato. Neurol Pediatr 1999;3:65-8.
37. Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalized seizures. Epilepsy Res 1996;25:191-7.
38. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36:S10-3.
39. Morimoto K, Sato H, Yamamoto Y. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997;38:966-74.
40. Sachdeo RC and the Tiagabine Study Group. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch Neurol 1997;54:595-601.
41. Adkins JC. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55:437-60.
42. Farnetani MA, Grosso S, Berardi R, Carpentieri ML, Morgese G, Balestri P. Tiagabina: efficacia terapeutica ed indicazioni cliniche. Esperienza dell'Istituto di Clinica Pediatrica dell'Universita di Siena - dati preliminari. Neurol Pediatr 1999;3:63-7.
43. Glauser TA. Topiramate. Seminar Pediatr Neurol 1997;4:34-42.
44. White HS, Skradski S. The novel antiepileptic drug topiramate (TPM) block kainate-evoked cobalt influx into cultured neurons. Epilepsia 1997;38:144-8.
45. Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999;837:263-9.
46. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7.
47. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;3:1324-8.
48. Elterman RD, Glauser TA, Wyllie E. A double blind, randomized trial of topiramate as adjuntive therapy for partial-onset seizure in children. Neurology 1999;52:1338-44.
49. Morelan EC, Griesemer DA, Holden KR. Topiramate for intractable childhood epilepsy. Seizure 1999;8:38-41.
50. Sachdeo RC, Glauser TA, Ritter F. A double blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882-7.
51. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILATIV). Epilepsy Res 1999;34:1-41.
52. Verrotti A, Morresi S, Basciani F, Cutarella R, Morgese G, Chiarelli F. Discontinuation of anticonvulsant therapy in children with partial epilepsy. Neurology 2000;55:1393-5.